作为重度抑郁症患者的辅助疗法:随机双盲第三期试验的结果
Suresh Durgam1,2, Willie R Earley1, Susan G Kozauer1
1Intra-Cellular Therapies, a Johnson & Johnson Company, Bedminster, New Jersey.
The Journal of clinical psychiatry
|August 28, 2025
概括
在抗抑郁药物治疗反应不足的重度抑郁症患者中,添加42毫克的卢马特显著改善了抑郁症症状. 治疗耐受性良好,并显示出良好的安全性.
科学领域:
- 精神病学
- 神经科学
- 药理学
背景情况:
- 主要抑郁症 (MDD) 是一个重大挑战,特别是在对标准抗抑郁药物治疗 (ADT) 反应不足的患者中.
- 需要新的治疗策略来解决这一患者群体的未满足需求.
- 这是一种新型抗精神病药物,可调节血清素,多巴胺和谷氨酸的神经传递.
研究的目的:
- 在患有MDD和ADT反应不足的成年患者中研究附加的lumateperone 42 mg的疗效和安全性.
- 评估lumateperone对抑郁症症状严重程度和整体疾病状态的影响.
主要方法:
- 这是一项3期随机双盲,安慰剂对照试验,涉及患有MDD的成人门诊患者 (18至65岁).
- 参与者对1-2个ADT和MADRS,CGI- S和QIDS- SR-16的特定基线得分反应不足.
- 患者接受了6周的辅助安慰剂 (n=243) 或42毫克卢马特佩龙 (n=242).
主要成果:
- 与安慰剂和ADT相比,在第43天的MADRS总得分 (LSMD = - 4. 9, P < . 0001) 和CGI- S得分 (LSMD = - 0. 7, P < .
- 通过QIDS-SR-16评估,患者报告的抑郁症也显示了用卢马特和ADT显著改善 (LSMD=-2. 4, P<. 0001).
- 常见的不良反应包括口腔干燥,疲劳和震. 体重增加或心脏代谢异常的风险很小,自杀念头的出现也很低.
结论:
- 在没有对ADT有充分反应的MDD患者中,辅助的lumateperone 42 mg有效改善抑郁症状和疾病严重程度.
- 在该患者群体中,卢马特的安全性概率表现良好.
- 这些研究结果支持lumateperone作为MDD治疗的潜在选择.
相关概念视频
01:23Antidepressant Drugs: MAOIs and Other Agents
340
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
340
01:27Depressive Disorders: MDD and Dysthymia
208
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
208
01:25Antidepressant Drugs: Overview
741
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
741
01:30Electroconvulsive Therapy
182
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
182
01:24Mania and Antimanic Drugs: Overview
318
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
318
01:26Drug Administration and Therapy Phases: Overview
738
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
738